Short Interest in PicoCELA Inc. (NASDAQ:PCLA) Declines By 76.2%

PicoCELA Inc. (NASDAQ:PCLA) saw a large decline in short interest in August. As of August 14th, there was short interest totaling 102,426 shares, a decline of 76.2% from the July 30th total of 429,834 shares. Approximately 269.5% of the company’s shares are short sold. Based on an average trading volume of 587,318 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in PicoCELA stock. XTX Topco Ltd acquired a new stake in PicoCELA Inc. (NASDAQ:PCLA) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 44,648 shares of the company’s stock, valued at approximately $72,000. XTX Topco Ltd owned approximately 0.16% of PicoCELA at the end of the most recent quarter.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Wall Street Zen raised shares of PicoCELA to a “hold” rating in a research note on Saturday, July 25th. Weiss Ratings raised shares of PicoCELA from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

PicoCELA Price Performance

Shares of PicoCELA stock opened at $6.97 on Friday. PicoCELA has a 52 week low of $1.35 and a 52 week high of $19.61. The stock has a 50 day moving average price of $5.74 and a two-hundred day moving average price of $4.43.

About PicoCELA

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.